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Disease epidemiology of (re-)emerging infectious diseases is changing rapidly, rendering 
surveillance of travel-associated illness important. 
Methods 
We evaluated travel-related illness encountered at EuroTravNet clinics, the European 
surveillance sub-network of GeoSentinel, between March 1, 1998 and March 31, 2018.  
Findings 
103,739 ill travellers were evaluated, including 11,239 (10.8%) migrants, 89,620 (86.4%) 
patients seen post-travel, and 2,880 (2.8%) during and after travel. Despite increasing 
numbers of patient encounters over 20 years, the regions of exposure by year of clinic 
visits have remained stable. In 5-year increments, greater proportions of patients were 
migrants or visiting friends and relatives (VFR); business travel-associated illness 
remained stable; tourism-related illness decreased. Falciparum malaria was amongst the 
most-frequently diagnosed illnesses with 5,254 cases (5.1% of all patients) and the most-
frequent cause of death (risk ratio versus all other illnesses 2.5:1). Animal exposures 
requiring rabies post-exposure prophylaxis increased from 0.7% (1998-2002) to 3.6% (2013-
2018). The proportion of patients with seasonal influenza increased from zero in 1998-2002 
to 0.9% in 2013-2018. There were 44 cases of viral haemorrhagic fever, most during the past 
five years. Arboviral infection numbers increased significantly as did the range of presenting 
arboviral diseases, Dengue and chikungunya diagnoses increased by 2.6% and 1%, 
respectively.  
Interpretation 
Travel medicine must adapt to serve  the changing profile of travellers, with an increase in 
migrants and persons visiting relatives and friends and the strong emergence of vector-
borne diseases, with potential for further local transmission in Europe. 
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Research in Context 
Evidence before this study 
Over the past 20 years, sentinel surveillance has emerged as a valuable tool to record and 
analyse trends in travellers importing infectious diseases from endemic areas to non-
endemic areas, providing insight in changing infectious diseases epidemiology worldwide 
and assisting physicians in making diagnostic and therapeutic decisions when caring for 
returning tourists and migrants. 
Added value of this study 
The dataset and analysis presented here is the most comprehensive published to date on 
chaning trends over time in travel medicine, focusing on infectious diseases imported into 
Europe.  
Implications of all the available evidence 
         
Detailed sentinel surveillance data contribute to recognising emerging and changing 
infectious diseases trends, and inform decision-making in pre- and post-travel care.   
 
Introduction 
The global population currently encompasses more than 7.6 billion people, growing at 
annual rates between 5 to 10%.1 The mobility within this population is well illustrated with 
609 million international tourist arrivals in 1998 and 1,408 in 2018, an increase of 130%,2 
with a constant upward future trend, particularly across emerging economies.3 At the same 
time, never have more people been displaced: an estimated 68.5 million, with more than 25 
million refugees worldwide; the majority of whom are under-age minors.4 This means that 
the prevention and treatment of illness associated with human mobility has become an 
increasingly important topic. 
 
The International Society of Travel Medicine’s (ISTM)5 European Travel and Tropical 
Medicine Network (EuroTravNet)6 is a sub-network of the global GeoSentinel Surveillance 
Network7, and currently includes 25 core sites. These are large-volume pre- and post-travel 
academic or clinical settings in twelve predominantly Western European countries6. The 
network captures travel-related illness in returning travellers and migrants as part of its 
portfolio. It contributes to detection, identification and management of imported infections, 
detection of outbreaks, and characterisation of trends in travel-related illness over time.8,9  
 
Here, we provide a 20-year analysis of travel-related illness presenting at EuroTravNet clinics 
and propose up-to-date priorities in travel medicine practice based on these trends.  
 
         
Methods 
Detailed methods for patient recruitment, inclusion criteria, diagnosis tests and limitations 
of the EuroTravNet and GeoSentinel databases have been described elsewhere.9,10 In brief, 
patients must have crossed an international border within the last 12 months before the 
clinic visit, and must have sought medical care for a presumed travel-related illness, both 
infectious or non-infectious, or for screening for asymptomatic infection. All travellers 
presenting to one of the EuroTravNet sites are systematically included in the GeoSentinel 
database. The diagnosis is based on specific clinical and/or laboratory diagnostic criteria for 
each infectious disease that are harmonised across sites through the use of a common set of 
specific definitions for each infection caused by a specific pathogen, or based on an 
infectious syndrome (with syndromic codes used when a clinical diagnosis is made and no 
specific aetiology is identified).9 The data collection protocol is classified as public health 
surveillance and not human subjects research, by the institutional review board officer at 
the United States National Center for Emerging and Zoonotic Infectious Diseases, at the 
Centers for Disease Control and Prevention (CDC).  
 
Travellers who presented between March 1, 1998 and March 31, 2018 to a EuroTravNet site 
with a travel-related illness were included. We evaluated two different clinical settings; 
patients who sought care during or after travel; and travellers whose only travel purpose was 
migration and were seen by a clinician after arrival in their destination country (referred to as 
migrants). Patients without a diagnosis yet, who were found to be healthy, or whose illness 
was not travel-related or the diagnosis was neither confirmed nor probable, were excluded. 
Diagnoses were analysed as a proportion of patients to control for the growth in number of 
patients seen over time. Because such a large sample size can result in statistically significant 
         
but clinically non-important differences and because denominator data to calculate risks is not 
available, we have limited statistical significance testing except to this very specific question 
of whether the proportion of patients with a disease increased or decreased over time. 
Grouping years into 5-year intervals was introduced to reduce year-to-year variability. 
The chi-square test was used to determine whether there is an association between any 
variable and the year of clinic visit (grouped into 5-year intervals: 1998-2002, 2003-2007, 
2008-2012 and 2013-2018). This analysis focuses on infectious diseases reports, constituting 
the vast majority of EuroTravNet records. Although the number of clinics in the network has 
increased, they continue to be large-volume pre- and post-travel academic or clinical settings. 
Because the number of clinics and patients has grown over time, all analyses over time 
examine the number of diagnoses as a proportion of the diagnoses reported in the same time 
period. We look at the number of diagnoses and the number as a proportion of the ill patients 
seen to analyse whether the amount of a disease has changed as a percentage of the patients 
we see. If the test was significant, the standardised residuals were examined to determine the 
largest contributions to the lack of independence. If the chi square test was significant and the 
association appeared monotonically increasing or decreasing, Somers’ D was used to test that 
hypothesis. Additional sensitivity analyses were performed based on only five clinics that 
joined the network in the first six years to assess the possibility that trends were due to the 
inclusion of new clinics. Data were analysed using Stata 14.2 for Windows (StataCorp LP, 
College Station, TX, USA).  
Role of the funding source 
The funders had no role in study design, data collection, data analysis, interpretation, and 
writing of the report.  
 
 
         
Results 
Cohort characteristics 
From March 1998 to March 2018, 25 centers in 13 countries contributed 119,826 
patient records. Over 20 years, the number of clinics participating in the network has 
grown. Five clinics joined early and others along the way; with a total of 25 having 
contributed data over the years. The number of patients reported has increased from 
6,267 in 1998-2002 to 51,162 during 2013-2018. After exclusion of 16,087 records, 
103,739 ill travellers were included in the analysis (Suppl. Table 1). Most 
(92,500/103,739; 89.2%) ill travellers were seen during or post-travel.  
There is a significant association between age group and the year of clinic visit 
(p<.0001). There was an  increase over time in the proportion of patients who were 
aged 10-20 (3% to 7%) and who are aged over 50 (17% to23%) and a decrease in the 
proportion of patients aged 30-40 (33% to 24%)(Supplementary Figure 1a). The 
proportion of patients who were female increased slightly from  47% to 49% (p=0.01) 
(Supplementary Figure 1b). 
There is a significant association between reason for travel and year of clinic visit 
(p<.0001). Analysing in 5-year increments, types of patients seen are becoming more 
diverse. Whilst business travel-associated illness remained stable, the association was 
driven by a decrease in the proportion of patients travelling for tourism, and 
correspondingly increasing proportions mainly of patients who were migrants or visited 
friends and relatives (VFR; 11% (11,239/103,739; 10.8%) (Figures 1a,b; 2a; 
Supplementary Figure 1c).  
Regarding top countries of exposure, small changes over time were seen, including for 
example decreases in the proportion visiting the Dominican Republic, and increases in the 
         
proportion exposed in Cameroon and Tanzania. There was a consistent decline in the 
proportion of ill travellers visiting North Africa (Egypt in particular) from Europe over the 
past two decades. Over all patient groups, the predominant region of exposure remained 
sub-Saharan Africa (Figure 2b), followed by Southeast Asia and the Indian subcontinent 
(Supplementary Figure 1d). Figure 2c presents the top 12 diagnoses in all patients by clinical 
setting, and by year of clinic visit (127,772 diagnoses). Figure 3 depicts the top diagnoses per 
geographical region (see Supplementary Table 2 for further details). Among 111,784 
diagnoses in the 92,500 patients seen during and after travel, acute diarrhea (n=10,395; 
9.3%), viral syndromes with or without rash (n=6,507; 5.8%) and Plasmodium falciparum 
malaria (n=4,897,4.4%)were the top three diagnoses. The top three of 15,988 diagnoses in 
11,239 migrants, resulting mainly from screening activities rather than constituting acute 
diagnoses, were chronic Chagas (Trypanosoma cruzi) disease (n=1,606; 10.1%), chronic 
hepatitis C (n=1,156; 7.2%), and latent tuberculosis (n=1,074; 6.7%).  Table 1 provides an 
overview on selected dignoses encountered over time. 
 
Deaths 
The overall death proportion was low (0.04%), with 45 deaths recorded in the 20-year 
observation period (Figure 1a,b). One six-year-old from the UK died from viral encephalitis 
(unconfirmed tick-borne encephalitis) with exposure in Germany. All other deaths occurred 
beyond the age of 30 years. Sixty-two percent of deaths occurred in men, who constituted 
only 51.1% of all ill patients reported. Among non-migrants, men were more likely to die 
than women (23/46,199 = 0.05% vs. 11/46,196 = 0.02%, p=.04),   although among migrants, 
more women died (6/4,481 = 0.13% vs. 5/6,748 = 0.07%, p=0.135). Proportionally, 2.7 times 
more migrants died compared to non-migrants (11/11,229 = 0.1%, and 34/92,395 = 0.04%, 
         
respectively). Overall, malaria patients had a 2.5:1 risk ratio of dying from their disease 
compared to patients with all other diagnoses (7/7,195 = 0.1% vs 38/96,544 = 0.04%). See 
Supplementary Table 3a,b for details of frequencies of causes of death in travellers’ cohorts 
and causes of death in this cohort.  
 
Malaria  
Malaria continues to be the number two diagnosis for patients seen during and after travel. 
Of all patients (travelers and migrants combined), 7,195 (6.9%) had malaria.  Of those, 6,370 
(88.5%) were from sub-Saharan Africa, of which 5,082 (79.8%) had P. falciparum malaria. 
Overall, P. falciparum malaria ranked third in this 20-year analysis with 5,254 cases (5.1% of 
all patients) (Figure 2c, 4a-c).  
3,407 of 7,195 (47.3%) of the malaria cases were in VFRs. The seasonality of EuroTravNet 
malaria diagnoses was stable, with an annual peak from June to October, correlating with 
school holidays. Among 11,239 migrants, 337 (3.0%) had P. falciparum malaria and 
204(1.8%) P. vivax malaria. P. knowlesi infections were reported in five tourists and business 
travelers who had visited Malaysia (three) and Thailand (two). A recent peak of P. vivax in 
2014-2015 with more than 100 cases annually in refugees is now back to pre-migration 
levels of 50-60 cases per year.9,11 
 
Arboviral diseases and viral haemorrhagic fevers 
There were significant increases in dengue diagnoses, in chikungunya diagnoses, in Zika 
diagnoses and in other arboviral diseases. In addition, the range of detected arboviral 
diseases increased among all ill patients (Table 1; Figure 2c). More recently, increases in 
         
imported yellow fever and West Nile fever cases were observed, and as well a surge of Zika 
cases during the recent large outbreaks in the Americas and globally.12,13 
According to case definition, there were 44 cases of viral haemorrhagic fever (VHF) seen in 
our cohort. The majority (n=29; 66.1%) were severe dengue infections. Of note, with the 
exception of one patient with yellow fever reported by the network14 and one with dengue 
haemorrhagic fever, all patients survived. Additional VHF patients included five with yellow 
fever, three with Ebola virus disease, three with Rift Valley fever, two with hantavirus, one 
with Crimean-Congo hemorrhagic fever (CCHF) and one with Lassa fever. There was a small 
significant increase in VHF cases over the study period with five VHF cases reported in the 
first quarter of 2018 alone (Supplementary Figure 2). 
 
Rabies  
Animal exposures leading to rabies post-exposure prophylaxis (RPEP) significantly increased 
over the time period and accounted for 2.6% (2,688/103,739) of all patients seen over the 
study period. Tourists accounted for the highest proportion (80.9%) of RPEP, followed by 
VFR travelers (11.3%). Overall, dogs were responsible for 46.1% of exposures followed by 
monkeys (22.8%), cats (12.7%) and bats (2.0%). Most travellers were exposed in Asia 
(53.8%), mainly South-east Asia (42.1%), followed by North Africa (12.4%), Latin America 
(8.8%), Middle East (7.5%) and sub-Saharan Africa (6.9%). In South-east Asia, monkeys were 
responsible for 43.3% of exposures.  
Rare diagnoses 
Unusual diagnoses are reported as well (Supplementary Table 4). There were significant 
increases in four unusual diagnoses, such as hepatic echinococcosis; leptospirosis;  
legionnaires disease and Shiga toxin-producing E. coli.  
         
Vaccine preventable diseases (VPD) 
Seasonal influenza, the most commonly diagnosed VPD, accounted for 0.6% (636/103,739) 
of all patients and increased significantly over the study period. Although not necessarily a 
VPD, proportions of patients with diagnoses of influenza-like-illness also increased 
significantly (Figure 2c; Supplementary Figure 3). There was a surge in 2009 in the number of 
patients reported with the novel H1N1 influenza strain (from 6 previously to 109). 
 
The next most-common VPDs were hepatitis A (219 patients) and hepatitis B (125 patients) 
which decreased as a percentage of ill patients over the study period. Other common VPDs 
were varicella (78 patients), pertussis (58), measles (45), mumps (25), rubella (14), TBE (13), 
diphtheria (8), yellow fever (5), and Japanese encephalitis (5).  Most VPDs were seen during 
or post-travel, although >20% of varicella patients (16/78), hepatitis B patients (33/125) and 
mumps patients (6/25) were migrants. The greatest proportion of VPDs was acquired in 
North America (primarily influenza), during air travel (primarily varicella) and in the Middle 
East (primarily influenza, especially from Saudi Arabia). The proportion of patients with a 
VPD who had sought pre-travel advice was 0.8% while it was 1.7% and 1.4% in those who 
had not, or whose status was not known, respectively.  The highest proportion of VPDs was 
seen in elderly travellers aged 70 and older (49/2,570; 1.9%), and young travellers aged 9 
years and younger (55/2,952; 1.9%). Looking specifically at measles, which has been 
undergoing a global resurgence, revealed the following regions of acquisition for the 45 
patients with measles: 16 from South-east Asia, 9 from sub-Saharan Africa, 7 from western 
Europe, 5 from South Central Asia and 8 from various other regions. Some of the most 
common countries of exposure included Thailand (8), Indonesia and France (4 each), and 
India (3). There was no increase over time in proportions of patients with measles. 
         
Discussion 
Analyses of surveillance data constitute a knowledge base for travel medicine practice.  
The strengths of the data include the large number of clinician-verified patient records 
(>100,000) on travel-associated illness, itinerary data, the 20-year data collection period 
allowing analysis over time, and the geographic representation of the European network 
sites. These factors ensure a realistic representation of travel-related illness in people 
seeking medical care in Europe. Also the size of the network improves the ability to use 
travelers as sentinels for disease outbreaks. 
 
Over time, the number of EuroTravNet sites and participating countries has grown and some 
sites have left the network; however, the network also has reflected changes in travel 
patterns.  The origin of migrants did change over time, due mainly to the additional Spanish 
sites seeing migrants from South America, and changes in the origin of major waves of 
migrants arriving in Europe.  Migrants from the Horn of Africa, mainly from Eritrea, led to a 
surge of P. vivax malaria reporting in recent years, in contrast to a traditional dominance of 
P. falciparum in West African migrants presenting in Europe.15  
 
Travel medicine needs to continue to adapt to global health challenges and changing disease 
epidemiology, in terms of, simplified, ‘who travels where to, and how’. It needs to account 
for (1) an increasing diversity and expansion of destinations; (2) a shift from ‘high income to 
middle-and low income country travel to a more diverse mixture of global movement; (3) 
the fact that the term ‘traveller’ should be interpreted broader and include migrants; (4) a 
finer granularity of creasingly accurate final diagnoses due to improved diagnostic capacities 
and capabilities; (5) a decrease in geopgraphic pixel size; (6) all aspects of post ’travel’ (in the 
         
broad sense of the word) care for vulnerable, immune-compromised, migrant and VRF 
individuals and populations; and (7), often discrete but meaningful changes in the 
composition of the mixture of travellers’ types, their age pattern, and the spectrum and 
distribution of exposure countries.  
 
With the massive volume growth of international travel, there is an ever-increasing number 
of travellers in terms of their origin as well as a diversification and expansion of destinations. 
In 1950, 97% of all tourists visited 15 top destinations whereas in 2015, only 54% of tourist 
arrivals were registered at these top destinations,3 with people visiting a wider range of 
remote destinations.  
 
Travel medicine focused almost exclusively on travel preparation and disease prevention. 
Now, the post-travel care component has emerged to share center-stage. Travel medicine 
previously focused on the traveler from high-income to middle- and low-income countries, 
whereas now, the care of travelers is much more multi-faceted. The term ‘traveller’ 
encompasses all cross-border movements globally, and includes migrants and VFRs as 
increasingly important groups; with the next step being to decrease ‘pixel size’ by 
acknowledging that in-country and intra-regional travel needs to be added to our definition 
of what constitutes a traveler, particularly if different ecosystems are spanned by one 
country’s borders.16 Reporting diligence, moving from analog to digital; bandwidth and 
accuracy of diagnoses as well as network sizes have expanded range and granularity of 
sentinel surveillance dramatically. Challenges, however, arise from the changing profile of 
travel-related illness, with rapid public health responses needed in case of highly-infectious, 
imported diseases such as filoviruses, Middle East respiratory syndrome coronavirus (MERS-
         
CoV), and monkeypox. A major trend is the emergence of greater numbers of ill travelers 
with arboviral diseases (possibly owed to a combination of more travellers being exposed, 
hence greater concern and greater numbers diagnosed because of improvements in 
diagnostics), with increases in dengue and chikungunya and the risk of introducing these 
infections into areas of southern Europe with susceptible vector populations and the 
emergence of not previously recorded infections such as Ross River virus disease, Japanese 
encephalitis, and Zika. This trend dictates that arthropod-bite prevention must become a 
central theme in travel medicine.17 Obviously, the epidemics in Latin America of chikungunya 
in 2013, and Zika in 2015/2016, and recent outbreaks of yellow fever in Brazil and Nigeria 
have led to increased diagnostic testing, which is a reflection of the growing appreciation of 
the clinical importance of these infections, which may have been grossly under-recognised in 
the past, and which may have brought unnecessary suffering upon patients, uncertain about 
their unexplained complaints.  Another challenge is the emergence of influenza, demanding 
improvements in diagnostics and case definitions for influenza-like-illness. 
 
Recognition of VPD not classically confined to ‘the tropics’ must become firmly integrated 
into routine pre-travel counselling. The pre-travel consultation presents an ideal opportunity 
to catch up on routine or missed vaccinations. The increasing risk of acquiring diseases in 
high-income countries is exemplified by measles18,19 due to increasing vaccine hesitancy,20 
and should capitalise on trends towards inoculation schemes that require less antigen, such 
as the intradermal route of application.21 The recent changes in rabies22 and yellow fever 
vaccination23 regimens are prominent examples.  
The occurrence of documented transmission of rabies from non-human primates (NHPs) to 
humans, although rare, implies that RPEP is indicated in patients injured by NHPs in rabies-
         
enzootic countries.24-27 Although there has been an increase in bites resulting in RPEP over 
the 20 years, it is likely that a significant proportion of tourists receiving RPEP following 
injuries caused by NHP in Asia are actually bitten by uninfected animals. Measures aiming at 
reducing contacts with NHP should be promoted among travellers. In addition, our analysis 
did not suggest an acute increase in the proportion of ill travellers with measles, although 
the database only includes patients until early 2018. However, a recent GeoSentinel analysis 
of all patients with measles reported since 201628 revealed an increase in confirmed and 
probable measles cases between 2016 to 2018, concurrent with the global resurgence of this 
disease.29 There is thus a clear need for pre-travel health providers to review measles 
vaccination status with travelers and make sure that they have been fully immunised. 
 
There is also a need to address inadequate post-travel care for vulnerable and hard-to-reach 
populations such as migrants and VFR-travelers. Their health care teams should incorporate 
travel medicine specialists, and recognise problems of public health importance such as the 
importation and establishment of autochthonous ‘tropical diseases’ in previously unafflicted 
areas (such as CCHF in Spain, chikungunya and other arthropod-borne viral diseases, or 
malaria in Southern European countries), and the exportation of VPDs by migrants fleeing 
economic instability and war.9,30 Finally, pre-travel care for immuno-compromised patients is 
an important evolving field within travel medicine; with the advent of powerful, targeted 
immunosuppressive medication, this patient group has become increasingly mobile and 
requires targeted travel medicine. Research on adapted vaccination strategies in this patient 
group is urgently required.31,32 
 
         
With any analysis and interpretation of sentinel surveillance data, an appreciation of the 
limitations of this methodological approach is paramount.  Denominator data are missing 
and the data presented here focus primarily on more severe infectious diseases and provide 
a synopsis of what travel medicine clinicians in specialised clinics typically diagnose. These 
data do not reflect precisely the full range of infectious illnesses contracted by travellers as 
all self-resolving conditions and those that are diagnosed by a general practitioner are not 
captured. A limitation of our study is that mortality data do not allow calculation of mortality 
risk for travelers, as our data do not capture the vast majority of deaths that are of non-
infectious causes or due to accidents and injuries.33 Furthermore, our data do not capture 
deaths of European travelers occurring during travel outside Europe.  
Another limitation is the changing number and profile of sites in EuroTravNet over time and 
therefore, analyses over time must be interpreted with some caution. In addition, diagnostic 
capacity has changed during the last 20 years and the sites’ capacity to make specific 
etiological diagnoses has improved. 
 
From a niche sub-specialty, travel medicine has emerged, and continues to evolve.  
Over time, there has been increased migrant and VFR travel. Arthropod bite prevention 
strategies must be improved, given the global increase in arthropod-borne infections, and 
the risk of their potential introduction into Europe in view of climate change and widespread 
suitable vector prevalence.  
 
Travel medicine is a multidisciplinary field that needs to recognise emerging and changing 
infectious disease trends and to inform the public, and tailor pre-travel advice to individual 
needs accordingly. It also needs to broaden its remit to address the health care needs of 
         
diverse populations, including migrants, medical tourists, and occupational groups who are 
at risk of travel-related illness. This speciality must also be alert to the potential for global 
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Table 1: Selected diagnoses reported between 1998 and 2018 (% of 103,739 patients) 
 










Malaria 526 (8.4%) 872 (6.8%) 2340 (7.0%) 3457 (6.8%)  





Chikungunya  0 50 (0.4%) 86 (0.3%) 608 (1.2%) 0.007* 
Zika, vector-associated 0 0 0 414 (0.8%) 0.007* 
Zika, not vector-associated  0 0 0 6  
Ross River  0 0 5 14  
Yellow fever  0 0 0 5  
Japanese encephalitis  0 0 1 4  
Tick-borne encephalitis 0 5 4 4  
West Nile  0 1 3 3  
Rift Valley Fever 0 0 2 1  
Barmah Forest  0 0 0 1  
Murray Valley encephalitis 0 0 0 1  
Other arbovirus 
infections** 
0 3 4 6  





Viral haemorrhagic fever 1 1 12 30 0.0003* 
Animal exposure leading to 
rabies vaccination 
41(0.7%) 222(1.7%) 602 (1.8%) 1823 (3.6%) 0.016* 
         
Influenza A and B 0 9 (0.1%) 158 (0.5%) 469 (0.9%) 0.006* 
Influenza-like-illness 18 (0.3%) 92 (0.7%) 551 (1.7%) 1295 (2.5%) 0.12* 
Acute hepatitis A or B 58 (0.9%) 59 (0.5%) 123 (0.4%) 103 (0.2%) -0.003* 
Measles 4 (0.1%) 3 (0.0%) 21 (0.1%) 17(0.0%)  
Viral syndrome with or 
without rash 
464 (7.4%) 1023 (7.9% 1851 (5.6%) 3225 
(6.29%) 
 
Upper respiratory tract 
infection 
265 (4.2%) 301 (2.3%) 660 (2.0%) 1008 (2.0%) -0.005* 
Total patients 6,301 12,895 33,301 51,242  
+ Somers’ D only calculated when N > 40 and proportions are monotonically increasing or decreasing over time, 
*=significant at 95% level 
**Others include sandfly fever/pappataci fever, sindbis fever, unspecified alphavirus, flavivirus and phlebovirus, 




Figure legends  
 
Figure 1a. Age and sex for ill travelers seen after or during travel. N=92,061 patients with 
age and sex known, 46,012 males and 46,049 females, 34 deaths.  
Figure 1b. Age and sex for ill travelers with migration travel only. N=11,201 patients with age 
and sex known, 6,737 males and 4,473 females, 11 deaths.  
Figure 2a. Travel reason and clinical setting by year of clinic visit; n = 103,739 patients. 
Figure 2b.  Region of exposure by year of clinic visit; n = 103,739 patients. 
Figure 2c. Top diagnoses in all patients by clinical setting by year of clinic visit; n = 127,772 
diagnoses. Multiple entries per patient possible.  
Figure 3.  Top 10 diagnoses by region of acquisition in travelers seen after travel. 
Fig 4a. Malaria species by 5 years, shown by % of malaria diagnoses.  
4b. Origin of malaria as Plasmodium species per region of acquisition, shown by % of malaria 
diagnoses per region.  
4c. Origin of malaria as Plasmodium species per region of acquisition, shown as numbers of 
patients.  
 
         
 
Figures 
Figure 1a. Age and sex for ill travelers seen after or during travel. N=92,061 patients with 




Figure 1b. Age and sex for ill travelers with migration travel only. N=11,201 patients with age 






         
Figure 2a. Travel reason and clinical setting by year of clinic visit; n = 103,739 patients. 
N patients  6267           12,870         33,295       51,162 
 
 
Medical care = travelers who travelled to seek medical care in another country 
VFR = Visiting friends and relatives 
M/V/R/A = Missionary, volunteers, researchers, aid worker 
 
Figure 2b.  Region of exposure by year of clinic visit; n = 103,739 patients. 
 Seen during or after travel       Migrants 
N pts.    5,814       11,907      29,828     44,951                          487          988          3,473         6,291  
 
 
         
 
Figure 2c. Top diagnoses in all patients by clinical setting by year of clinic visit; n = 127,772 
diagnoses – large pie charts all travelers including migrants; satellite pie charts migrants. 







Figure 3. Top 10 diagnoses by region of acquisition in travelers seen after travel. 
 
 





Number  (n)(% of all travellers seen” post-travel” included in the analysis) after returning 
from the regions shown: South America n=6,947 (7.75%), Central America and Caribbean 
n=6775 (7.56%), North America n=640(0.71%), Western Europe n=3,190 (3.56%), Sub-
Saharan Africa n=27,493 (30.68%), South central Asia, n=11,254 (12.56%) South-east Asia 
n=17,237 (19.23%), Oceania n=379 (0.42%), Australia/New Zealand n=391 (0.44%) 
Abbreviations: ARI – acute respiratory infections; CLM - cutaneous larva migrans; STDs: 
sexually transmitted diseases; PEP – post-exposure prophylaxis 
 
Figure 4a. Malaria species by five years (7,515 malaria diagnoses in 7,195/103,739 
individuals). 
 
N patients  526           872            2340          3457 
% severe or  
         
complicated  3.2%   3.2%            5.6%           8.9%  
N drug  
Resistant   3      5               1                              9 
 
*93 double infections, 3 triple infections 
 
4b. Origin of malaria as Plasmodium species per region of acquisition, shown by % of malaria 
diagnoses per region.  
 
*93 double infections, 3 triple infections 
 
  
         
4c. Origin of malaria as Plasmodium species per region of acquisition, shown by number of 
malaria diagnoses by region.  
 






         
